Stock Watch: Vaccines Dominate Second-Quarter Earnings
The Second Half Of 2021 May Be About Different Vaccines
Executive Summary
Pfizer’s earnings were skewed by its coronavirus vaccine for the second quarter running while GSK’s vaccine sales were helped by the catch-up on pediatric immunization schedules. Sales of influenza vaccines may come to the fore in the second half.
You may also be interested in...
Stock Watch: Non-COVID-19 Vaccines Under The Pandemic
A rebound in non-COVID-19 vaccine sales in the second year of the pandemic might have been expected but was instead muted, deferring more favorable comparisons for another year.
GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.
Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business
The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.